Abstract
Mucopolysaccharidosis I (MPS I) is a lysosomal storage disease due to α-L-iduronidase (IDUA) deficiency that results in the accumulation of glycosaminoglycans (GAG). Systemic gene therapy to MPS I mice can reduce lysosomal storage in the brain, but few data are available regarding the effect upon behavioral function. We investigated the effect of gene therapy with a long-terminal-repeat (LTR)-intact retroviral vector or a self-inactivating (SIN) vector on behavioral function in MPS I mice. The LTR vector was injected intravenously to 6-week-old MPS I mice, and the SIN vector was given to neonatal or 6-week-old mice. Adult-LTR, neonatal-SIN, and adult-SIN-treated mice achieved serum IDUA activity of 235 ± 20 (84-fold normal), 127 ± 10, and 71 ± 7 U/ml, respectively. All groups had reduction in histochemical evidence of lysosomal storage in the brain, with the adult-LTR group showing the best response, while adult-LTR mice had reductions in lysosomal storage in the cristae of the vestibular system. Behavioral evaluation was performed at 8 months. Untreated MPS I mice had a markedly reduced ability to hold onto an inverted screen or climb down a pole. LTR-vector-treated mice had marked improvements on both of these tests, whereas neonatal-SIN mice showed improvement in the pole test. We conclude that both vectors can reduce brain disease in MPS I mice, with the LTR vector achieving higher serum IDUA levels and better correction. Vestibular abnormalities may contribute to mobility problems in patients with MPS I, and gene therapy may reduce symptoms.
Similar content being viewed by others
References
Aldenhoven M, Boelens JJ, de Koning TJ (2008) The Clinical Outcome of Hurler Syndrome after Stem Cell Transplantation. Biol Blood Marrow Transplant 14:485–498
Aronovich EL, Bell JB, Khan SA et al (2009) Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther 17:1136–1144
Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017
Baldo G, Wu S, Howe R et al (2011) Pathogenesis of aortic dilatation in MPS VII mice may involve complement activation. Mol Genet Metab 104:608–619
Banks WA (2004) Are the extracellular pathways a conduit for the delivery of therapeutics to the brain. Curr Pharm Des 10:1365–1370
Chung S, Ma X, Liu Y, Lee D, Tittiger M, Ponder KP (2007) Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol Genet Metab 90:181–192
Ciron C, Desmaris N, Colle MA et al (2006) Gene therapy of the brain in the dog model of Hurler’s syndrome. Ann Neurol 60:204–213
Di Domenico C, Di Napoli D, Gonzalez Y et al (2006) Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. Hum Gene Ther 17:1112–1121
Ellinwood NM, Ausseil J, Desmaris N et al (2011) Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 19:251–259
Fuller GN, Burger PC (2007) Central nervous system. In: Mills S (ed) Histology for Pathologists, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 273–319
Garbuzova-Davis S, Louis MK, Haller EM, Derasari HM, Rawls AE, Sanberg PR (2011) Blood-brain barrier impairment in an animal model of MPS III B. PLoS One 6:e16601
Grubb JH, Vogler C, Levy B, Galvin N, Tan Y, Sly WS (2008) Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 105:2616–2621
Hartung SD, Frandsen JL, Pan D et al (2004) Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther 9:866–875
Heldermon CD, Hennig AK, Ohlemiller KK et al (2007) Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS One 2:e772
Kakkis ED, Muenzer J, Tiller GE et al (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344:182–188
Kobayashi H, Carbonaro D, Pepper K et al (2005) neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther 11:776–789
Liu Y, Xu L, Hennig AK et al (2005) Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol Ther 11:35–47
Ma X, Liu Y, Tittiger M et al (2007) Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol Ther 15:889–902
Metcalf J, Ma X, Linders B, Wu S et al (2010) A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice. Mol Ther 18:334–342
Neufeld EF, Muenzer J (2001) The Mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Metabolic and Molecular Basis of Inherited Disease. McGraw Hill, New York, pp 3421–3452
Ohlemiller KK, Hennig AK, Lett JM, Heidbreder AF, Sands MS (2002) Inner ear pathology in the mucopolysaccharidosis VII mouse. Hear Res 16:969–984
Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF (2003) Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 100:1902–1907
Osborne MJ, McElmurry RT, Lees CJ et al (2011) Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther 19:450–460
Pan D, Sciascia A, Vorhees C, Williams MT (2008) Progression of multiple behavior deficits with various age of onsets in a murine model of Hurler syndrome. Brain Res 1188:241–253
Ponder KP, Haskins ME (2007) Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 7:1333–1345
Reolon GK, Braga LM, Camassola M et al (2006) Long-term memory for aversive training is impaired in IDUA-/- mice, a genetic model of mucopolysaccharidosis type I. Brain Res 1076:225–230
Reolon GK, Reinke A, de Oliveira MR et al (2009) Alterations in oxidative markers in the cerebellum and peripheral organs in MPS I mice. Cell Mol Neurobiol 29:443–448
Schachern PA, Cureoglu S, Tsuprun V, Paparella MM, Whitley CB (2007) Age-related functional and histopathological changes of the ear in the MPS I mouse. Int J Pediatr Otorhinolaryngol 71:197–203
Staba SL, Escolar ML, Poe M et al (2004) Cord-blood transplants from unrelated donors in patients with Hurler’s syndrome. N Engl J Med 350:1960–1969
Thomas JA, Beck M, Clarke JT, Cox GF (2010) Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis 33:421–427
Trobridge GD (2011) Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opin Biol Ther 11:581–593
Visigalli I, Delai S, Politi LS et al (2010) Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116:5130–5139
Vogler C, Levy B, Grubb JH et al (2005) Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 102:14777–14782
Walkley SU (2004) Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol 15:433–444
Wang D, Zhang W, Kalfa TA et al (2009a) Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci USA 106:19958–19963
Wang RY, Cambray-Forker EJ, Ohanian K et al (2009b) Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II. Mol Genet Metab 98:406–411
Watson G, Bastacky J, Belichenko P et al (2006) Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther 13:917–925
Wolf DA, Lenander AW, Nan Z et al (2011) Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis 43:123–133
Wozniak DF, Hartman RE, Boyle MP et al (2004) Apoptotic neurodegeneration induced by ethanol in neonatal mice is associated with profound learning/memory deficits in juveniles followed by progressive functional recovery in adults. Neurobiol Dis 17:403–414
Wozniak DF, Xiao M, Xu L, Yamada KA, Ornitz DM (2007) Impaired spatial learning and defective theta burst induced LTP in mice lacking fibroblast growth factor 14. Neurobiol Dis 26:4–26
Wraith JE, Beck M, Lane R et al (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 120:e37–e46
Acknowledgments
We thank Elizabeth Neufeld for sending us the MPS I mice, and Sara Conyers for performing behavioral tests. This work was supported by the Ryan Foundation, the National MPS Society, and the National Institutes of Health (DK66448 awarded to KPP). Histology was supported by P30 DC004665 awarded to R. Chole, and behavioral studies were supported by NIH Neuroscience Blueprint Interdisciplinary Center Core Grant P30 NS057105 awarded to Washington University (DFW). GB received a scholarship from the Conselho Nacional de Desenvolvimento Cientifico (CNPq) of Brazil (200584/2010-3).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by: Maurizio Scarpa
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(PDF 2,303 kb)
Rights and permissions
About this article
Cite this article
Baldo, G., Wozniak, D.F., Ohlemiller, K.K. et al. Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits. J Inherit Metab Dis 36, 499–512 (2013). https://doi.org/10.1007/s10545-012-9530-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-012-9530-x